White House Says All States Joined Medicaid Drug-Price Model—Savings Are Still Projections

Administration reports nationwide participation

WASHINGTON — All 50 states, Washington, D.C., and Puerto Rico have signed on to participate in the federal GENEROUS Medicaid drug-pricing model, according to a White House official cited Friday by Reuters and the Associated Press.

The participation claim marks a major expansion for a program that CMS launched as voluntary for both states and drug manufacturers. CMS's public model page still describes the process as a five-year test in which participating manufacturers provide supplemental rebates to bring the net Medicaid price of included drugs closer to prices in selected countries.

The reviewed federal model page identifies September 10 as the state application deadline but did not display a public, state-by-state roster at publication time. The nationwide count is therefore an administration claim corroborated by two independent news organizations reporting the same planned White House announcement, not a roster independently reconstructed by What’s the Scoop With Broach.

What the model changes—and what it does not

GENEROUS works through supplemental rebates. CMS negotiates pricing and standardized coverage criteria with participating manufacturers; participating state Medicaid programs then enter the required agreements and invoice manufacturers for rebates intended to produce the internationally aligned net price.

That structure targets what Medicaid programs and taxpayers ultimately spend on selected covered outpatient drugs. It does not create a direct payment to Medicaid beneficiaries, send a rebate check to patients or guarantee that every prescription will cost less at the pharmacy counter.

Medicaid beneficiaries generally already face only nominal prescription copayments under federal rules. KFF's independent analysis says the model does not change those out-of-pocket limits. Potential benefits to patients could instead come through broader access if negotiated coverage criteria are less restrictive, but the same criteria could also affect prior authorization or step-therapy rules and must be evaluated drug by drug.

The $64.2 billion figure is a forecast, not booked savings

Reuters reports that the White House Council of Economic Advisers projects $27.6 billion in state savings and $36.6 billion in federal savings over 10 years—a combined $64.2 billion. Those figures are forecasts based on administration assumptions, not money already saved or an independently audited result.

AP reports that key manufacturer deals remain confidential, making their impact difficult to verify. A separate $529 billion figure cited by the White House in May concerned a broader set of drug-pricing agreements and should not be substituted for the narrower GENEROUS estimate reported Friday.

Medicaid already receives mandatory and state-negotiated manufacturer rebates. KFF found that existing rebates reduced gross Medicaid drug spending by 53% on average from fiscal 2019 through 2024. That existing discount structure means the new model's additional savings will depend on which manufacturers and drugs are included, current state rebate arrangements, utilization and the negotiated coverage terms.

California is included in the reported count

Because the White House account says all 50 states joined, California's Medi-Cal program is included in the reported participation total. The sources reviewed for this breaking report did not include a separate California Department of Health Care Services announcement specifying which drugs Medi-Cal will select or how its current supplemental rebate agreements compare with the federal terms.

State participation is not the same as immediate use of an international price for every covered drug. CMS says states can review negotiated pricing and key terms, must enter the necessary supplemental rebate agreements and must align applicable coverage policies with Medicaid managed-care organizations.

For California readers, the next useful records will be a state participation agreement or plan amendment, a list of selected model drugs, coverage criteria and a fiscal estimate showing how the deal changes Medi-Cal spending compared with existing rebates.

Confirmed facts and important limits

Confirmed in the public record: CMS created the voluntary five-year GENEROUS model; it uses supplemental rebates tied to selected international prices; and CMS says participating states and manufacturers must execute agreements and adopt negotiated coverage terms.

Reported Friday by Reuters and AP: a White House official says every state, Washington, D.C., and Puerto Rico signed on. Not yet demonstrated by a public state-by-state roster reviewed for this report: each jurisdiction's final drug selections, its negotiated net prices, or its projected savings.

Not established: that every Medicaid prescription will receive a lower price, that patients will get cash rebates, that copays will fall, that the projected $64.2 billion has already been realized or that confidential agreements will remain unchanged through 2030. What’s the Scoop With Broach will update this report when CMS publishes the participant roster, drug list or audited results.

About the image

The accompanying photograph shows the Hubert H. Humphrey Building in Washington, headquarters of the U.S. Department of Health and Human Services, which oversees CMS. Carol M. Highsmith created the photograph in 2012, and the Library of Congress makes it available without known publication restrictions; Wikimedia Commons identifies it as public domain.

It is an authentic file photograph of the federal agency headquarters connected to the policy. It does not depict Friday's planned White House announcement, a Medicaid beneficiary, a participating state official, a prescription drug, a pharmacy transaction or a price negotiation.